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A B S T R A C T
Consumption of dietary supplements and specifically niche products such as supplements targeting pregnant
women is increasing. The advantages of dietary supplementation during pregnancy with folic acid have been
established, but health effects of many other supplements have not been confirmed. EU and US legislation on
dietary supplements requires the product to be safe for the direct consumer, the mother. Long-term health effects
for the fetus due to fetal programming (in utero adaptation of the fetal epigenome due to environmental stimuli
such as supplementation) are not taken into account. Such epigenetic alterations can, however, influence the
response to health challenges in adulthood. We therefore call for both conducting research in birth cohorts and
animal studies to identify potential health effects in progeny of supplement consuming mothers as well as the
establishment of a nutrivigilance scheme to identify favorable and adverse effects post-marketing. The acquired
knowledge can be used to create more effective legislation on dietary supplement intake during pregnancy for
safety of the child. Increasing knowledge on the effects of consuming supplements will create a safer environ-
ment for future mothers and their offspring to optimize their health before, during and after pregnancy.
1. Introduction
The popularity of dietary supplements, in this paper defined as
sources of concentrated micro- or macronutrients, is rising together
with an increasing interest of consumers in potential health enhancing
foods (Euromonitor International, 2015; Menrad, 2003; Teichner and
Lesko, 2013). Especially niche products, such as dietary supplements
that target women of reproductive age and pregnant women, increased
their market share over the past decade. For example, from 2010 to
2015, the multivitamin market yearly grew 2 to 19 percent in the eight
countries with the highest sales of multivitamins (UK, Brazil, USA,
Russia, Mexico, Italy, South Korea and China). In the UK alone, the sales
of multivitamins targeting pregnant women grew approximately two
percent in these five years, ending up representing 17% of the total
multivitamin market in the UK (Schmidt, 2015). Although the avail-
ability of epidemiological data is limited, cross-sectional and cohort
studies suggest an increase in daily use of supplements (Kim et al.,
2014; Radimer et al., 2004; Sullivan et al., 2009). Different studies
report that females use different dietary supplements more often than
men and especially those persons with increased interest in health were
more regularly consumers of dietary supplements (Bailey et al., 2011;
Dickinson et al., 2014; Radimer et al., 2004; Rock, 2007). Additionally,
in specific subgroups including athletes and long-term cancer survivors
at reproductive age, the use of dietary supplements has increased
(Knapik et al., 2016; Velicer and Ulrich, 2008; Wardenaar et al., 2016).
The beneficial effect of dietary supplementation before and during
pregnancy has only been established for folic acid: folic acid is im-
portant for growth and development of both the fetus and maternal
tissues and a sufficient intake of folic acid can be guaranteed by sup-
plementing the diet (De-Regil et al., 2015; EFSA NDA Panel, 2009;
Eichholzer et al., 2006; Kaiser and Allen, 2008). In various countries,
foods are (required to be) fortified with folic acid, whilst the European
strategy is to advise the target group (women with the intention to
become pregnant and pregnant women) to supplement their diet
(Czeizel et al., 2013). Whereas fortification can reach a broader public,
it is suggested to expose the general public to too high amounts of folic
acid while a large part of the target group may still not meet their re-
commended daily intake (Czeizel et al., 2013; Osterhues et al., 2013).
Women of childbearing age and pregnant women have been reported to
increasingly use dietary supplements with other ingredients such as the
omega-3 polyunsaturated fatty acid docohexaenoic acid (DHA), cal-
cium, vitamin D, zinc and multivitamins, but also with herbal in-
gredients such as Echinacea and ginger (Buppasiri et al., 2015; Cave
et al., 2016; De-Regil et al., 2016; Imhoff-Kunsch et al., 2012; Ota et al.,
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2015; Picciano and McGuire, 2009; Tsui et al., 2001). However, when a
woman is not malnourished during pregnancy, the use of supplements
other than folic acid is not proven to be beneficial and its consumption
is questionable (Darnton-Hill and Mkparu, 2015; Ladipo, 2000). The
maternal diet before and during pregnancy, and even during breast-
feeding, has been shown to induce phenotypic changes in offspring
which may affect the offspring's health status. Obviously, dietary
components can elicit such alterations through the placenta and post-
partum through the nutritional values of breast milk, but these studies
did not unveil clear cut relationships between the intake of specific
nutrients by the mother and health status of their children (Hambidge
et al., 2014; Netting et al., 2014; Ramakrishnan et al., 2012).
The safety of such dietary supplements consumed during pregnancy
is often not specifically studied (Friedman, 2000; Schweitzer, 2006).
Although teratogenic effects of compounds are important in safety as-
sessments (European Parliament and Council of the European Union,
2015), the effects of supplement intake on the long-term health of the
fetus seems to be addressed to a much lesser extent. It is however
generally acknowledged that the dietary intake (both the quality and
the quantity of the diet) and dietary status of pregnant women can
affect the development of the fetus which subsequently influences
health in adult life (Godfrey and Barker, 2001; Lillycrop and Burdge,
2014). This is exemplified by dietary supplementation with folic acid
during pregnancy: whilst supplementation in the first trimester of
pregnancy is beneficial for health of the offspring, using folic acid
supplements later in pregnancy is suggested to increase the risk to de-
velop allergic diseases and asthma (Eichholzer et al., 2006; Whitrow
et al., 2009).
With the increasing awareness about fetal development being in-
fluenced by the maternal diet, this paper illustrates how food supple-
ment safety is regulated and why long-term safety is important to be
taken into account in safety regulations.
2. Regulating dietary supplement safety
Safety is key in the regulation of dietary supplements. Rules and
regulations dealing with dietary supplement safety do however not
seem to consider the consequences that consuming such products can
have on the offspring of the consumer. In Europe, dietary supplements
are regulated by Directive 2002/46/EC, the so-called Food Supplement
Directive (FSD) (European Parliament and Council of the European
Union, 2002). The FSD defines food supplements as ‘concentrated
sources of nutrients or other substances with a nutritional or physiological
effect’, which are aimed to supplement the normal diet (European
Parliament and Council of the European Union, 2002). Medicinal pro-
ducts are specifically excluded under this Directive. Since dietary sup-
plements are categorized as food products, these supplements must
comply with other relevant food legislation. The framework regulation
concerning foods, the General Food Law (GFL), describes food safety as
one of the general principles for food products to be allowed to be
placed on the market (European Parliament and Council, 2002). Al-
though the GFL does not provide a definition for food safety, food is
described to be unsafe when a product is (a) injurious to health or (b)
unfit for human consumption (European Parliament and Council,
2002). In determining whether a product is injurious to health, Article
14 (4) (a) of the GFL specifies that effects on subsequent generations
should also be assessed (European Parliament and Council, 2002), next
to the short- and/or long-term effects on the direct consumer. Since no
specific requirements are however mentioned, this article leaves room
for interpretation.
In the United States, the Dietary Supplement Health and Education
Act of 1994 (DSHEA) regulates food supplements separately from
conventional foods and food additives (Dietary Supplement Health and
Education Act of 1994; U.S. Congress). The DSHEA defines supplements
as ‘any product which contains one or more dietary ingredients such as vi-
tamins, minerals, herbs or other botanicals, amino acids or other ingredients
used to supplement the diet’ (Dietary Supplement Health and Education
Act of 1994, n.d.). Although food products should be safe when they are
available for sale, no specific safety dossier is required before dietary
supplements are placed on the market. The DSHEA gives the Food and
Drug Administration (FDA) in the USA the authority to safeguard the
public from unsafe products (Dietary Supplement Health and Education
Act of 1994, n.d.; U.S. Food and Drug Administration, 2014). Therefore,
adequate information must be provided to the FDA before a new dietary
ingredient can be brought to market and when the FDA shows that the
dietary ingredient poses a ‘significant or unreasonable risk’ to consumer
safety, the product can be removed from the market (Dietary
Supplement Health and Education Act of 1994, n.d.). Currently, how-
ever, the long-term effects of dietary supplements consumed during
pregnancy or during breastfeeding are insufficiently known to make a
proper decision about potential risks and consumer safety. In Europe,
only new ingredients or products produced by new techniques are
subject to the safety review of the European Food Safety Authority
(EFSA), a crucial aspect in the pre-market authorization by the Eur-
opean Commission for such a novel food under the Novel Food Reg-
ulation (Regulation (EU) 2015/2283) (European Parliament and
Council of the European Union, 2015; Turck et al., 2016). The European
Commission has described in their recommendation that the whole-
someness of food products, influenced by i.a. the nutritional, tox-
icological and metabolic properties of a product, is key in assessing the
authorization of a novel food (European Commission, 1997; Turck
et al., 2016). Next to considering the nutritional implications of a novel
food, this recommendation also suggests to take short and long term
effects of consuming a novel food into account and to pay specific at-
tention therein to groups with specific nutritional requirements, such as
pregnant and lactating women (European Commission, 1997). The
health effects of offspring in later life do however not seem to be taken
into consideration when safety is tested. As the effects of the maternal
dietary status and maternal consumption during pregnancy on the de-
velopment of the fetus become more apparent, the question arises how
these findings can be incorporated in legislation, and specifically in
dietary supplement regulation.
3. Fetal programming
Before birth, the fetus is affected by various environmental factors
such as maternal dietary status, food intake or the intake of dietary
supplements by the mother (Fig. 1). The fetus is thought to adapt to
these in utero circumstances by making changes to the epigenome that
are potentially necessary for survival, which can persist in later life
(Gicquel et al., 2008; Godfrey and Barker, 2001; Vanhees et al., 2014).
In short, the epigenome includes various chemical changes to the
structure of DNA without changing the underlying DNA sequence.
These chemical changes can be either on the DNA bases (e.g., methy-
lation of cytosine in CpG sequences) or on proteins that are involved in
folding the DNA (e.g., histone modifications). These epigenetic mod-
ifications are involved in regulating gene expression and therefore af-
fect growth and tissue differentiation, especially in the developing
child. Moreover, these modifications can be passed down to the off-
spring via transgenerational epigenetic inheritance. The DNA sequence
in the genome is largely static within an individual, but the epigenome
is dynamic and can be altered by environmental conditions, especially
by dietary habits (Vanhees et al., 2014). These adaptations to the en-
vironmental circumstances by the fetal epigenome may result in altered
structures and functioning of the organism, which is also known under
different terms, including ‘phenotype induction’, ‘fetal programming’
(Burdge et al., 2007; Gicquel et al., 2008; Godfrey et al., 2013; Godfrey
and Barker, 2001; Vanhees et al., 2014) or the ‘Developmental origins
of (adult) health and disease’ (DOHAD) hypothesis (47–50). Since dif-
ferent organ systems develop on various critical time points, environ-
mental stimuli or triggers can influence the development of the fetus
differently (Al-Ghazali et al., 1989; Barker, 2012; Chmurzynska, 2010;
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Godfrey and Barker, 2001).
As depicted in Fig. 1, stable alterations to the fetal epigenome
prevail later in life and can influence the response to environmental
stimuli in adulthood (Brenseke et al., 2013; Gicquel et al., 2008;
Godfrey et al., 2007). When later in life environmental conditions in-
teract with the altered epigenome, this mismatch of environmental
stimuli with the altered epigenome can increase the risk of developing
diseases. An example of such a mismatch was shown in children that
were in utero during the Dutch Famine (hunger winter of 1944–1945).
These children have an increased risk for obesity, not because of the
protein and caloric deficiency only, but because they additionally en-
countered a Western type of diet later in life leading to a mismatch
between the in utero environment and the environment in adulthood
(Gluckman, 2004; Grandjean, 2008; Roseboom et al., 2001). Animal
models of obesity (mothers consuming hyper-caloric diets) also de-
monstrated negative effects in offspring such as increased systolic blood
pressure and higher fasting plasma insulin (Brenseke et al., 2013;
Roseboom et al., 2011; Vickers et al., 2000), indicating that not only
under-nutrition, but also over-nutrition can have ‘programming’ con-
sequences.
4. Dietary supplementation and fetal programming
Various reviews have shown that the maternal dietary intake in-
fluences the health status of offspring (Burdge et al., 2007;
Chmurzynska, 2010; Lillycrop, 2011). Micronutrients are well known
modulators of the epigenome (for instance the effect of vitamin D on the
epigenome (Fetahu et al., 2014) and various roles of nutrients in epi-
genetic processes reviewed in (Choi and Friso, 2010)). These reviews
however mainly focus on the potential negative effects of deficiencies of
the maternal diet or negative consequences following the intake of a
sub-optimal maternal diet, whereas the current trend towards opti-
mizing health is also focusing on women of childbearing age not ne-
cessarily heaving deficiencies (Schmidt, 2015). Supplement use by
pregnant women is therefore expected to rise. The following four short
cases illustrate why also intake of dietary supplements with con-
centrated nutrients in a healthy maternal dietary status and the off-
spring's health, should somehow be taken into account in future safety
regulations. Evidence for the programming effect of folic acid is mainly
coming from studies in humans, whereas the long term effects of certain
flavonoids (e.g., quercetin and genistein) on offsprings' health originates
predominantly from animal studies.
4.1. Folic acid
Since 1992, dietary supplementation with folic acid is re-
commended to decrease the risk on neural tube defects (Eichholzer
et al., 2006; Gezondheidsraad, 2008). Although this effect of folic acid
has been established by epidemiological studies, the exact effect of folic
acid on the multistep process of developing the human neural tube is
however still not completely understood (Osterhues et al., 2013). Folic
acid can for instance act as a co-enzyme and affects the construction
and repair of DNA (Czeizel et al., 2013). The supplementation of 0.4
mg/day folic acid during the first trimester of pregnancy is considered
as safe for both the women and their unborn children and it should be
noted that the widely recommended use of folic acid before and during
pregnancy is undisputed to minimize the risk for neural tube defects as
well as other congenital malformations (De-Regil et al., 2015;
Eichholzer et al., 2006). Supplements consumed by the mother before
or during the fetal development could however affect the fetal epi-
genome (Pauwels et al., 2017). Various cohort studies and reviews
suggest that maternal supplementation with folic acid in late pregnancy
can lead to an increased risk for developing asthma or other (allergic)
diseases in childhood. However, these data are postulated by studies of
varying quality and results are inconclusive (Greenop et al., 2014;
Håberg et al., 2009; Magdelijns et al., 2011; Martinussen et al., 2012;
Schüz et al., 2007; Wang et al., 2015; Whitrow et al., 2009). Still,
epidemiological studies performed so far, do not consider the presence
of potential triggers or challenges, for instance exposure to allergens,
and whether children of mothers who took folic acid supplements react
Fig. 1. How prenatal environmental factors could influence the response to health challenges in adulthood.
Before birth, the fetus is affected by various environmental factors such as the maternal dietary status, food intake or the intake of dietary supplements by the mother. These en-
vironmental factors could result in changes to the epigenome, through which the fetus adjusts to these environmental conditions. When these changes are unfavorable, it can result in
teratogenic effects or childhood diseases. When these epigenetic alterations are not immediately unfavorable, they will prevail later in life. These adaptations to the genome can affect the
response of an individual to various health challenges as obesity and high blood pressure, or cigarette smoke or allergen exposure later in life. The epigenetic alterations due to prenatal
environmental factors (such as the intake of dietary supplements) can thereby influence the response to such health challenges in adulthood. These responses should be monitored by a
nutrivigilance scheme, a system to monitor and report (adverse) events which are attributed to the consumption of food supplements, novel foods or any other food related product.
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differently to these allergens. Additionally, a recent study by Pauwels
et al. (2017) suggests that maternal dietary or supplemental intake of
methyl-group donors (including folate) can influence the infant's DNA
methylation patterns in genes related to metabolism, growth, appetite
regulation, and maintenance of DNA methylation reactions. Thus, al-
though maternal folic acid supplementation during pregnancy is un-
disputed, a follow up at later stages in the child's life is warranted to
further optimize the dose of folic acid or to optimally select the time-
window during pregnancy at which additional intake of folic acid
should be recommended.
4.2. Quercetin
Dietary intake of supplements containing flavonoids and anti-
oxidants in general is popular amongst pregnant women (Barenys et al.,
2016). Consequences of dietary supplementation with the flavonoid
quercetin on the offspring's health have been established in several
animal studies (Vanhees et al., 2013, 2012; 2011b). Quercetin is a
dietary antioxidant, found mainly in onions, apples and tea, which is
claimed to have various beneficial health effects as antioxidant and
anti-inflammatory properties (Aherne and O'Brien, 2002; Boots et al.,
2008; Vanhees et al., 2012). The average daily dietary intake of quer-
cetin in humans with a Western type of diet is 4–68 mg per day (Skibola
and Smith, 2000), but a much higher intake can be reached because the
daily dose of quercetin supplements lies between 200 and 1800 mg
quercetin (manufacturers' recommendations) (Egert et al., 2008;
Mennen et al., 2005). These high dose supplements are freely available
in pharmacies and drugstores. Therefore, daily quercetin supple-
mentation, which results in increased plasma quercetin levels (Egert
et al., 2008), can lead to increased exposures of the fetus to high con-
centrations of quercetin and its metabolites. Feeding very high doses of
quercetin (333 mg/kg feed) to pregnant mice did not appear to be
teratogenic to their fetuses (Prater et al., 2008), but long term health
effects have been described: in mice, the maternal consumption of
quercetin is shown to upregulate the gene expression of enzymatic
antioxidants in offspring and the response of hepatic cells to oxidative
stress seems to be altered (Vanhees et al., 2013, 2012). This could
theoretically improve the health status of the offspring by decreasing
oxidative stress markers, as well as potentially protecting against in-
duced DNA adduct formation (Vanhees et al., 2012, 2011b). On the
other hand, relatively high prenatal concentrations of quercetin were
also shown to lead to increased iron storage in the liver, which could
put the offspring at risk for a toxic iron overload (Vanhees et al.,
2011b).
4.3. Phyto-estrogens
Adults consuming modest amounts of soy-containing foods have a
total daily isoflavone intake of 1–9 mg. However, people who consume
large amounts of soy products, like vegetarians, have a higher intake of
isoflavones such as genistein and daidzein. In Asian countries the daily
intake of isoflavones can reach 20–40 mg, because of the high con-
sumption of soy (Skibola and Smith, 2000). Intake of genistein sup-
plements is becoming increasingly popular, especially for women, be-
cause it is suggested to result in decreased breast cancer risk (Coward
et al., 1993). The manufacturers of supplements recommend a dose of
up to 6 tablets of 25–100 mg per day. Additionally, it should be noted
that the metabolism of these isoflavones is different in the fetus, and as
a result, fetal cord blood contains higher concentrations of for instance
genistein than maternal blood (Coward et al., 1993). Intake by young
children can also be high, when they are being fed with soy-based
formulas (also see the American Academy of Pediatrics statement on Use
of Soy Protein-Based Formulas in Infant Feeding from 2008 (Bhatia and
Greer, 2008)). However, there is concern about the intake of iso-
flavones like genistein during pregnancy, because it mimics the human
hormone estrogen (therefore it is called a phyto-estrogen). Animal
studies indeed indicate that intake of genistein during pregnancy
changes the epigenetic landscape of offspring (Dolinoy et al., 2006)
with subsequent changes in gene expression (Vanhees et al., 2011a).
Moreover, maternal intake of genistein has been related to early onset
of puberty in female offspring and alters the development of breast
tissue, potentially leading to increased breast cancer risk in offspring at
older ages (Hilakivi-Clarke et al., 2002; n.d.; Warri et al., 2008).
4.4. Multi micronutrient supplementation
Recently, a Cochrane systematic review on the safety of multi mi-
cronutrient supplement intake during pregnancy was published (Haider
and Bhutta, 2015). Most of the studies that were included in the ana-
lyses were carried out in low and middle-income countries, where mi-
cronutrient deficiency is common among women of reproductive age. It
was concluded that supplementation of pregnant women is beneficial
with regard to preventing low birth weight and small for gestational age
(SGA) pregnancies, whereas in studies that involved pregnant women of
Western countries no such beneficial effects were found. Although the
authors correctly conclude that interventions with micronutrients
during pregnancy should focus on developing countries, it may also
lead to additional intake of micronutrients by pregnant women in
Western countries, because high intake of micronutrients is generally
considered to be safe; better safe than sorry. However, in that same
Cochrane review, safety was only assessed on basis of perinatal health
only (e.g., preeclampsia, preterm births, maternal anemia, maternal
and neonatal mortality, congenital abnormalities etc.), whereas long
time health could not be studied. Taking into account the phenomenon
of developmental programming, claiming safety of relatively high doses
of micronutrients by supplementation may be premature. How should
regulators thus deal with this uncertainty?
5. Epigenetic modulation in safety regulation
Long term effects of dietary supplements are thought to be mediated
via epigenetic mechanisms. The role of epigenetics in reproductive
toxicity is discussed in a recent report on the 2015 ECETOC workshop
‘The Role of Epigenetics in Reproductive Toxicity’, and the use of epi-
genetic findings in legislation was one major point of discussion
(European Centre for Ecotoxicology and Toxicology of Chemicals,
2015). However, current knowledge is too limited and therefore legis-
lative acts have not incorporated this aspect of safety yet.
Since the consumption of dietary supplements does not immediately
give rise to adverse effects, it would not be realistic to ban these pro-
ducts form the market until such effects are fully identified. It would
therefore be helpful to keep track of these potential negative effects via
a nutrivigilance scheme: a system in which adverse events that are at-
tributed to food supplement intake or any other product related to food
can be reported (ANSES - French Agency for Food Environmental and
Occupational Health and Safety, 2014; Rihouey-Robini, 2014). In re-
sponse to the thalidomide-affair in the 1960s, where birth defects in
children were caused by thalidomide intake during pregnancy, so-
called pharmacovigilance systems were developed to report adverse
drug reactions after the drug was placed on the market (de Boer et al.,
2015). A nutrivigilance scheme, where reports concerning adverse re-
sponses following food supplement or functional food consumption can
be filed by health professionals, producers and distributors, has so far
only been established in France (ANSES - French Agency for Food
Environmental and Occupational Health and Safety, 2014; Rihouey-
Robini, 2014). By establishing a specific system to report adverse events
and incidents with various food products as food supplements and novel
foods, potential risks can be identified and thereby the scheme can
contribute to consumer safety (Fig. 1).
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6. Future perspectives
The consumption of supplements by women of childbearing age and
pregnant women is expected to rise (Schmidt, 2015). The limited epi-
demiological data available indicate that many pregnant women con-
sume dietary supplements and this number is thought to increase
(Radimer et al., 2004; Sullivan et al., 2009). Although supplementing
the diet with folic acid has proven health benefits, many other sup-
plements used during pregnancy are currently not proven to be bene-
ficial, unless they are used to compensate for deficiencies. With the
maternal diet affecting the fetal genome through developmental pro-
gramming, the consequences of supplementing should not be under-
estimated. We do not suggest that consuming dietary supplements en-
danger the health of the fetus, yet recognize the current lack of
knowledge on the long-term health effects of the maternal diet, and
more specifically supplements, on offspring. Next to a nutrivigilance
scheme, currently ongoing birth-cohorts and animal studies could help
to identify potential adverse and favorable health effects in progeny of
supplement consuming mothers.
Birth-cohorts could be very helpful in discovering and possibly
quantifying relationships between dietary intake of the mother and
potential adverse or beneficial health effects in progeny. Other addi-
tional information on fetal programming could originate from animal
studies, in which it is possible to consider the effects of specific en-
vironmental stimuli on the adapted and maturated genome. In the study
design, the consumption of dietary supplements by pregnant animals
could be followed by exposure of the mature offspring to environmental
stimuli including smoking, exposure to chemicals or use of pharma-
ceutical products. Although such studies could be helpful in identifying
long term effects of prenatal exposure to dietary supplements, results
obtained by animal studies can never fully clarify the effects found in
humans. Therefore, the ultimate effects can only be evaluated by
combining results obtained in animal and human studies with post-
marketing events found via a nutrivigilance monitoring scheme.
Although foods are generally considered to be safe, in most cases the
safety of these products in pregnancy is not required to be tested and
therefore not established (Friedman, 2000; Schweitzer, 2006). This
current lack of knowledge on safety and the need for scientific evidence
regarding the health effects on offspring give rise to our call to develop
a nutrivigilance scheme, by which adverse and favorable effects due to
the consumption of specifically dietary supplements can be identified.
Increasing knowledge on the effects of consuming supplements will
create more effective legislation and thereby a safer environment for
future mothers to optimize the health of their children before and
during pregnancy.
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